118 related articles for article (PubMed ID: 34183163)
1. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
Jia N; Che X; Jiang Y; Zhu M; Yang T; Feng W
Gynecol Oncol; 2021 Sep; 162(3):788-796. PubMed ID: 34183163
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
4. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
5. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Hong DS; Moore KN; Bendell JC; Karp DD; Wang JS; Ulahannan SV; Jones S; Wu W; Donoho GP; Ding Y; Capen A; Wang X; Bence Lin A; Patel MR
Clin Cancer Res; 2021 Apr; 27(7):1864-1874. PubMed ID: 33495309
[TBL] [Abstract][Full Text] [Related]
6. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM
Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194
[TBL] [Abstract][Full Text] [Related]
9. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
Schrauwen S; Coenegrachts L; Cattaneo A; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Aug; 138(2):378-82. PubMed ID: 26050920
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
[TBL] [Abstract][Full Text] [Related]
12. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
[TBL] [Abstract][Full Text] [Related]
13. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
14. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
[TBL] [Abstract][Full Text] [Related]
16. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
17. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Zaidi AH; Kosovec JE; Matsui D; Omstead AN; Raj M; Rao RR; Biederman RWW; Finley GG; Landreneau RJ; Kelly RJ; Jobe BA
Ann Surg; 2017 Jul; 266(1):91-98. PubMed ID: 27471841
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
[TBL] [Abstract][Full Text] [Related]
20. Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity
Zheng L; Li H; Mo Y; Qi G; Liu B; Zhao J
Oncotarget; 2017 Nov; 8(58):98964-98973. PubMed ID: 29228741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
